Gaylis Norman B, Sagliani Joanne, Black Shawn, Tang Kezhen L, DeHoratius Raphael, Kafka Wesley A, Parenti Dennis
Arthritis & Rheumatic Disease Specialties, Aventura, FL, USA.
Medical Affairs Rheumatology, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Patient Prefer Adherence. 2017 Sep 12;11:1543-1553. doi: 10.2147/PPA.S136567. eCollection 2017.
To evaluate patient perspectives regarding utilization of intravenous (IV) therapy for inflammatory arthritis (IA).
This was a single-center, noninterventional, patient questionnaire-based study of adult IA patients currently receiving IV biologics. At a single visit, patients completed the questionnaire comprising 30 questions centered on their experience receiving an intravenously administered therapy to treat their IA. The questionnaire included questions on patient demographics, disease characteristics, and previous biologic treatment for IA (subcutaneous [SC] and IV). Patients rated their level of agreement with statements regarding satisfaction with current IV biologic therapy and potential advantages and disadvantages of IV biologic therapy using a 5-point Likert scale (1= strongly disagree, 5= strongly agree).
One hundred patients were enrolled and completed the survey; 66% were female and the mean age was 58 years. Before IV treatment, 97% of patients received information regarding therapy options. Ninety patients ranked their satisfaction with current IV therapy as 4 or 5. The proportion of patients with an "extremely favorable" perception of IV therapy increased from 33% to 71% following initiation of their current medication. Thirty-one patients had previously received SC therapies to treat their IA.
These results demonstrated an overall favorable perception of IV therapy among this patient population. Patients previously treated with SC therapy also had a positive shift in the perception of IV therapy after initiating IV therapy. Patients' perception and preference for treatment options should be highly considered by the treating physician during or as part of a shared decision-making process.
评估患者对炎症性关节炎（IA）静脉注射（IV）治疗的看法。
这是一项基于患者问卷的单中心、非干预性研究，研究对象为目前正在接受静脉注射生物制剂的成年IA患者。在一次就诊时，患者完成了一份包含30个问题的问卷，这些问题围绕他们接受静脉注射治疗IA的经历展开。问卷包括患者人口统计学、疾病特征以及IA既往生物治疗（皮下注射[SC]和静脉注射）的问题。患者使用5点李克特量表（1 = 强烈不同意，5 = 强烈同意）对关于当前静脉注射生物治疗满意度以及静脉注射生物治疗潜在优缺点的陈述的同意程度进行评分。
招募了100名患者并完成了调查；66%为女性，平均年龄为58岁。在接受静脉注射治疗前，97%的患者收到了关于治疗方案的信息。90名患者将他们对当前静脉注射治疗的满意度评为4或5。在开始当前用药后，对静脉注射治疗有“极其良好”看法的患者比例从33%增加到了71%。31名患者此前接受过皮下注射治疗IA。
这些结果表明该患者群体对静脉注射治疗总体看法良好。此前接受过皮下注射治疗的患者在开始静脉注射治疗后对静脉注射治疗的看法也有积极转变。治疗医生在共同决策过程中或作为其一部分时，应高度考虑患者对治疗方案的看法和偏好。
